Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

The following is a summary of “Complement is increased in treatment resistant rectal cancer and modulates radioresistance.,” published in the September 2024 issue of Oncology by O’Brien et al.

During the past 20 years, the advent of neoadjuvant, primary ... compared with surgical resection with or without adjuvant treatment. Second, chemotherapy can act as a radiosensitizer, improving ...

Definitive treatment of muscle invasive bladder cancer depends on neoadjuvant chemotherapy and surgery, or trimodality therapy with maximal resection followed by chemoradiation therapy. (UroToday.com) ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Neoadjuvant chemotherapy prior to surgery and postoperative radiation therapy could improve organ preservation in patients ...

Given as neoadjuvant treatment, TAR-200 plus cetrelimab generated responses in patients with muscle-invasive bladder cancer.

Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b ...